Showing 2861-2870 of 3315 results for "".
- Santen Launches Ducressa Post-Cataract Surgery Antibiotic/Steroid Combinationhttps://modernod.com/news/santen-launches-ducressa-post-cataract-surgery-antibiotic-steroid-combination/2478828/Santen EMEA has announced the launch of Ducressa, a fixed dose combination of levofloxacin/dexamethasone eye drops solution indicated for the prevention and treatment of inflammation, and the prevention of infection a
- Immunovant Announces Voluntary Pause in Clinical Dosing of IMVT-1401 for Thyroid Eye Diseasehttps://modernod.com/news/immunovant-announces-voluntary-pause-in-clinical-dosing-of-imvt-1401-for-thyroid-eye-disease/2478829/Immunovant announced a voluntary pause of dosing in its ongoing clinical trials of its investigational drug IMVT-1401 for the treatment of Thyroid Eye Disease (TED). The company has become aware of a physiological signal consisting of elevated total cholesterol and LDL levels
- Center For Sight is the First Practice Worldwide to Offer the OptiBlue IOLhttps://modernod.com/news/center-for-sight-is-the-first-practice-worldwide-to-offer-the-optiblue-iol/2478793/Center For Sight, which operates 14 eye clinics and surgery centers in Southwest Florida, is the first eye care practice to offer the new OptiBlue IOLs (Johnson & Johnson Vision), an advanced intraocular lens technology that filters violet light to improve contrast and clarity for cataract pa
- Rayner Enters Canadian Ophthalmology Markethttps://modernod.com/news/rayner-enters-canadian-ophthalmology-market/2478773/Following the recent approval of incorporation, Rayner announced that is will now be offering the Rayner portfolio of IOLs and injectors directly to Canadian surgeons. The entry into the Canadian market will be led by Wade Allen, Director: Americas, Rayner Surgical Corp. The RayOne Aspheri
- More Adults with Vision Loss Seeking Help Staying Connected During Pandemichttps://modernod.com/news/more-adults-with-vision-loss-seeking-help-staying-connected-during-pandemic/2478772/Since the onset of COVID-19 those with visual impairments have faced disproportionate vulnerabilities from living in extended isolation. Newly released data has shown that clinical depression within the visually impaired community is being reported at nearly three times the level than the general
- GenSight Biologics Announces Publication of Results from Lumevoq RESCUE Phase 3 Trialhttps://modernod.com/news/gensight-biologics-announces-publication-of-results-from-lumevoq-rescue-phase-3-trial/2478755/GenSight Biologics announced that Ophthalmology has published results from the RESCUE pivotal phase 3 clinical trial of Lumevoq gene therapy in ND4 Leber Hereditary Optic Neuropathy (LHON) subjects. The paper, published in the January issue under the title, “Efficacy and safety
- Johnson & Johnson Vision Releases New Guide to Help Slow the Progression of Myopia in Childrenhttps://modernod.com/news/johnson-johnson-vision-releases-new-guide-to-help-slow-the-progression-of-myopia-in-children/2478750/Johnson & Johnson Vision announced a new guide with recommendations for eye care professionals to assess, monitor and treat myopia in children. The guide, titled “Managing Myopia: A Clinical Response to the Growing Epidemic,” is a result of a year of collaboration with lead
- Aviceda Therapeutics Announces Formation of Executive Teamhttps://modernod.com/news/aviceda-therapeutics-announces-formation-of-executive-team/2478745/Aviceda Therapeutics has announced the composition of the Executive Team that will guide the company through ongoing development of first-in-class therapeutics and continued growth opportunities as a business entity. Aviceda’s lead ophthalmic optimized nanoparticle, as an intravitreal form
- EyeSouth Partners Expands Network to Include 28 Doctors in Ohio and Kentucky Through Affiliation with Midwest Eye Centerhttps://modernod.com/news/eyesouth-partners-expands-network-to-include-28-doctors-in-ohio-and-kentucky-through-affiliation-with-midwest-eye-center/2478742/EyeSouth Partners has announced that it has completed an affiliation with Midwest Eye Center (MWEC), representing EyeSouth’s first in the states of Ohio and Kentucky. Terms of the deal were not disclosed. Midwest Eye Center is led by Drs. Mark Cepela, Jean Noll, Faiz Khaja, Saif Jaw
- ProQR Completes Enrollment of its Pivotal Trial of Sepofarsen for the Treatment of LCA10https://modernod.com/news/proqr-completes-enrollment-of-its-pivotal-trial-of-sepofarsen-for-the-treatment-of-lca10/2478728/ProQR Therapeutics announced it has completed patient enrollment in its phase 2/3 Illuminate study of sepofarsen for the treatment of Leber Congenital Amaurosis 10 (LCA10) due to the p.Cys998X mutation in the CEP290 gene. With enrollment completed, topline results are expected in the first half (